glp-1/gip dual agonist weight loss Understand Tirzepatide and Its Effect on Current Therapy GIPR/GLP-1R dual agonist therapies for

Clin Exp Immunol

For broader regulatory context, see FDA Peptide Reclassification 2026: What It Means for Canadian Researchers

The observed decrease in BMI supports the significance of weight control in the treatment of IIH and the connection between obesity-related processes and elevated intracranial pressure

FDA Food and Drug Administration

Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA

Any episode of syncope (loss of consciousness) requires immediate medical assessment, as this may indicate significant hypotension or other serious conditions requiring investigation